Regen BioPharma Inc
Close on Oct 19, 2026
- Market cap
- $92.33K
- P/E (TTM)
- –
- Dividend yield
- –
About Regen BioPharma
Pharmaceutical Preparations, SIC 2834
Regen Biopharma, Inc. is a biotechnology company focused on developing regenerative medicine therapies. The company targets treatments across oncology and aplastic anemia, with therapeutic candidates including HemaXellerate, dCellVax, tCellVax, DiffronC, and DuraCar, alongside patented small molecules targeting NR2F6. Its programs incorporate cellular compositions, siRNA gene silencing, mRNA cancer vaccines, and CAR-T cell engineering. Regen Biopharma advances its pipeline through internal development and commercialization partnerships, including licensing arrangements that grant external entities rights to apply its technologies toward veterinary therapeutics and human pancreatic cancer treatments.
The company conducts its developmental operations within the United States alongside its wholly owned subsidiary, KCL Therapeutics, Inc. Regen Biopharma maintains its principal executive offices in La Mesa, California.
Summary of the business section of Regen BioPharma's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Regen BioPharma Inc
- Founded
- 2012
- Headquarters
- La Mesa, CA
- Address
- 4700 Spring St #304 91942
- Phone
- (619) 722-5505
- Employees
- 1, Sep 30, 2024
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Nevada
- Fiscal year ends
- September 30
- Auditor
- BCRG Group, Irvine, CA
Stock & identifiers
- Ticker
- RGBP
- Other tickers
- RGBPP
- Exchange
- OTC
- IPO date
- Oct 6, 2014
- Shares outstanding
- 1.68B, Aug 12, 2026
- Public float
- $1.05M, Mar 31, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 2-for-1, Feb 10, 2026; 2-for-1, Nov 4, 2024; 3-for-1, Jul 5, 2024; 1-for-1500 reverse, Mar 6, 2023; 1-for-1500 reverse, Mar 6, 2023
- SEC CIK
- 1589150
- EIN
- 45-5192997
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Regen BioPharma's leadership is listed in its proxy statement (Form DEF 14A).
Employees
Headcount reported in annual reports
“As of April 30, 2025, the Company has 1 full time employee.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 13, 2026 | Late filing | Notification of late filing |
| Jul 15, 2026 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Apr 7, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Dec 26, 2024 | Deregistration | Termination of SEC registration (Form 15) |
| May 29, 2024 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| May 10, 2024 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jul 29, 2019 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| May 14, 2019 | Late filing | Notification of late filing |
| Apr 10, 2019 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Dec 28, 2017 | Late filing | Notification of late filing |
| Oct 24, 2016 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Dec 30, 2015 | Late filing | Notification of late filing |